Capsida Biotherapeutics

Capsida Biotherapeutics is developing next generation, targeted genetic medicines for rare and more common neurological and ocular diseases across all ages. The company's founding technology originated in the lab of Caltech's Viviana Gradinaru, Ph.D. Founded in 2019, Capsida is financed by Versant Ventures and Westlake Village BioPartners and has entered into strategic collaborations with AbbVie, CRISPR Therapeutics, and Lilly's Gene Therapy Division.

Capsida Biotherapeutics is developing next generation, targeted genetic medicines for rare and more common neurological and ocular diseases across all ages. The company's founding technology originated in the lab of Caltech's Viviana Gradinaru, Ph.D. Founded in 2019, Capsida is financed by Versant Ventures and Westlake Village BioPartners and has entered into strategic collaborations with AbbVie, CRISPR Therapeutics, and Lilly's Gene Therapy Division.

1. Capsida Biotherapeutics - Engineering novel AAVs and developing the next generation of gene therapies
2. About - Capsida Biotherapeutics
3. Capsida Biotherapeutics (United States)